Wisconsin Pharmacal recalls MG217 Multi-Symptom Treatment Cream due to confirmed Staphylococcus Aureus contamination. This non-sterile product poses a microbial risk. Consumers should check lot numbers and contact the company for details.
“Wisconsin Pharmacal MG217 Cream Recall: Staphylococcus Aureus Contamination Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31333-wisconsin-pharmacal-mg217-cream-recall-staphylococcus-aureus-contamination-risk. Based on FDA recall #D-0553-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0553-2026%22&limit=1).
The FDA announced on April 24, 2026, that Wisconsin Pharmacal Company is recalling MG217 Multi-Symptom Treatment Cream due to confirmed Staphylococcus Aureus contamination. The voluntary Class I recall affects 690 tubes distributed nationwide and in the Bahamas.
The product contains the confirmed presence of Staphylococcus Aureus, a microbial contaminant in non-sterile products. The FDA classified this as a Class I recall, indicating a high risk of adverse health consequences.
Context
GovInfoNow's records show Wisconsin Pharmacal Company has one other recall on record since October 3, 2014, involving CVS pharmacy Pain Relieving Antiseptic Spray tested positive for microbial growth. Other recent recalls of similar products include Blaine Labs Revitaderm Gel Recall (April 8, 2026), Trifluent Pharma Wound Care Gel Recall (April 8, 2026), and Blaine Labs Revitaderm Wound Gel Recall (April 8, 2026).
How to tell if you have this one
Check the product label for the lot number 1024088, which expires November 30, 2026. The cream is sold in 6-ounce containers with a colloidal oatmeal 2% formula.
Brand
Wisconsin Pharmacal Company
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Label
Look for the lot number 1024088 on the label to confirm if your cream is recalled.
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
Nationwide
Not listed
FDA distribution: “USA Nationwide and Bahamas” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA published this recall 33 days after the firm started it.
1Firm started the recall
2Published in FDA’s Enforcement Report
3FDA classified it Class I
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0553-2026 (April 24, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0553-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.